The following is a summary of “Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity,” published in the ...

Rheumatoid arthritis (RA) is associated with a higher rate of heart failure subtypes, according to a study published o ...

Understanding how patients with heart failure with preserved ejection fraction (HFPEF ... Key mortality risk factors, including age, gender, body mass index, burden of co-morbidities, and coronary ...

Rates of heart failure with preserved ejection fraction (HFpEF) were doubled in patients with rheumatoid arthritis (RA) ...

A new study published in the Frontiers in Cardiovascular Medicine journal showed that right ventricular (RV) dysfunction is ...

[18] All of these factors ... and ejection fraction ≥45% who were hospitalized for heart failure during the last 6 months or had persistent class III or IV symptoms. As with the CHARM-Preserved ...

ANSWER: Heart failure is simply when the heart is unable to pump all the blood it needs to meet the body’s demands. Heart ...

According to research conducted by Johns Hopkins University, a form of heart failure known as heart failure with a preserved ejection fraction ... or cardiovascular risk factors you may have.

Heart failure with preserved ejection fraction (HFpEF) is underdiagnosed in patients with severe secondary tricuspid regurgitation (STR) of undefined etiology (isolated STR).

For patients with heart failure with preserved ejection fraction, tirzepatide yields a reduced risk for a composite of death from cardiovascular causes or worsening heart failure.

BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) is a major health concern. Pathological stimuli and interactions between cardiac fibroblasts (CFs) and other cell types may lead to ...

SGLT2 inhibitors plus finerenone may have a protective effect against cardiovascular events in patients with HFpEF or HFmrEF.